These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22493742)

  • 1. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.
    Jenq RR; Curran MA; Goldberg GL; Liu C; Allison JP; van den Brink MR
    PLoS One; 2012; 7(4):e35222. PubMed ID: 22493742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
    Frey AB; Cestari S
    Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
    Shafer-Weaver KA; Watkins SK; Anderson MJ; Draper LJ; Malyguine A; Alvord WG; Greenberg NM; Hurwitz AA
    Cancer Res; 2009 Aug; 69(15):6256-64. PubMed ID: 19622771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens.
    Yi H; Yu X; Guo C; Manjili MH; Repasky EA; Wang XY
    Cancer Immunol Immunother; 2011 Mar; 60(3):349-60. PubMed ID: 21088965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
    Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
    J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance.
    Hermann-Kleiter N; Klepsch V; Wallner S; Siegmund K; Klepsch S; Tuzlak S; Villunger A; Kaminski S; Pfeifhofer-Obermair C; Gruber T; Wolf D; Baier G
    Cell Rep; 2015 Sep; 12(12):2072-85. PubMed ID: 26387951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer.
    Ward-Kavanagh LK; Zhu J; Cooper TK; Schell TD
    Cancer Immunol Res; 2014 Aug; 2(8):777-88. PubMed ID: 24801834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.
    Bak SP; Barnkob MS; Wittrup KD; Chen J
    Cancer Immunol Res; 2013 Dec; 1(6):393-401. PubMed ID: 24778132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.
    Liu Z; Noh HS; Chen J; Kim JH; Falo LD; You Z
    J Immunol; 2008 Sep; 181(6):4363-70. PubMed ID: 18768895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.
    Nesbeth YC; Martinez DG; Toraya S; Scarlett UK; Cubillos-Ruiz JR; Rutkowski MR; Conejo-Garcia JR
    J Immunol; 2010 May; 184(10):5654-62. PubMed ID: 20400704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of subcutaneous tumor with adoptively transferred T cells.
    Peng L; Shu S; Krauss JC
    Cell Immunol; 1997 May; 178(1):24-32. PubMed ID: 9184695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells.
    Shand JC; Qin H; Nasholm N; Capitini CM; Fry TJ
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):26-36. PubMed ID: 24141010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.
    Holler A; Zech M; Ghorashian S; Pike R; Hotblack A; Veliça P; Xue SA; Chakraverty R; Morris EC; Stauss HJ
    Haematologica; 2016 Apr; 101(4):482-90. PubMed ID: 26802053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.
    Capitini CM; Nasholm NM; Duncan BB; Guimond M; Fry TJ
    J Immunol; 2013 Feb; 190(3):1351-9. PubMed ID: 23275602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
    Simons BW; Cannella F; Rowley DT; Viscidi RP
    Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
    Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
    Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens.
    Friedman TM; Jones SC; Statton D; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):224-35. PubMed ID: 15077221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
    Bullock TN; Mullins DW; Colella TA; Engelhard VH
    J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.